<div id="readability-page-1"><p><span>Phreesia (NYSE:PHR - Get Free Report)</span> was downgraded by research analysts at Barclays from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a note issued to investors on Thursday,Zacks.com reports.</p><ul><li>Phreesia Hits Bottom in Q1: Rebound Ahead, Timing Uncertain</li></ul><p>Other analysts also recently issued research reports about the stock. Mizuho dropped their target price on shares of Phreesia from $22.00 to $19.00 and set an &#34;outperform&#34; rating on the stock in a research report on Tuesday, March 24th. DA Davidson decreased their price objective on shares of Phreesia from $35.00 to $30.00 and set a &#34;buy&#34; rating for the company in a research note on Friday, January 23rd. Citizens Jmp  reiterated a &#34;market perform&#34; rating on shares of Phreesia in a research note on Wednesday, April 1st. Citigroup  reiterated a &#34;neutral&#34; rating and issued a $10.00 target price (down from $25.00) on shares of Phreesia in a research note on Tuesday, March 31st. Finally, BMO Capital Markets reduced their price objective on shares of Phreesia from $32.00 to $14.00 and set an &#34;outperform&#34; rating for the company in a research report on Tuesday, March 31st. Eleven analysts have rated the stock with a Buy rating, seven have issued  a Hold rating and one  has given a Sell rating to the stock. Based on data from MarketBeat.com, Phreesia  has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $20.00.</p><p><b>Read Our Latest Research Report on PHR</b></p><h2>Phreesia Trading Up 0.1%</h2><ul><li>Can Waystar Still Stand Up to Rising Competition?</li></ul><p>NYSE:PHR opened at $8.78 on Thursday. The firm has a 50-day simple moving average of $9.94 and a 200-day simple moving average of $14.53. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.53 and a current ratio of 1.53. Phreesia has a one year low of $7.77 and a one year high of $32.76. The firm has a market cap of $533.29 million, a P/E ratio of 292.57 and a beta of 0.89. </p><p>Phreesia (NYSE:PHR - Get Free Report) last issued its quarterly earnings data on Monday, March 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.07 by ($0.05). Phreesia had a return on equity of 3.23% and a net margin of 0.48%.The firm had revenue of $127.07 million during the quarter, compared to analysts' expectations of $126.75 million. During the same period in the previous year, the firm earned ($0.11) EPS. The firm's quarterly revenue was up 15.9% on a year-over-year basis.  Equities analysts anticipate that  Phreesia will post 0.28 EPS for the current fiscal year. </p><h2>Insider Activity</h2><ul><li>Phreesia Stock is a Healthcare IT Play </li></ul><p>In other news, insider David Linetsky sold 8,332 shares of the firm's stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average price of $8.07, for a total transaction of $67,239.24. Following the completion of the sale, the insider owned 224,056 shares in the company, valued at $1,808,131.92. This trade represents a 3.59% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Balaji Gandhi sold 3,829 shares of the stock in a transaction dated Wednesday, March 25th. The stock was sold at an average price of $11.26, for a total transaction of $43,114.54. Following the transaction, the chief financial officer directly owned 146,740 shares of the company's stock, valued at approximately $1,652,292.40. This trade represents a 2.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 50,493 shares of company stock worth $461,983 over the last quarter. 5.50% of the stock is currently owned by corporate insiders. </p><h2>Institutional Inflows and Outflows</h2><p>Several hedge funds have recently bought and sold shares of the stock. Raymond James Financial Inc. boosted its stake in  Phreesia by 2.7% during the second quarter. Raymond James Financial Inc. now owns 14,049 shares of the company's stock worth $400,000 after buying an additional 375 shares during the period.  Alliancebernstein L.P. boosted its stake in  Phreesia by 1.3% during the third quarter. Alliancebernstein L.P. now owns 62,712 shares of the company's stock worth $1,475,000 after buying an additional 812 shares during the period.  Van ECK Associates Corp boosted its stake in  Phreesia by 78.7% during the fourth quarter. Van ECK Associates Corp now owns 2,502 shares of the company's stock worth $42,000 after buying an additional 1,102 shares during the period.  Arizona State Retirement System boosted its stake in  Phreesia by 8.1% during the third quarter. Arizona State Retirement System now owns 17,608 shares of the company's stock worth $414,000 after buying an additional 1,313 shares during the period.  Finally, Federated Hermes Inc. purchased a new position in  Phreesia during the third quarter worth about $32,000. Hedge funds and other institutional investors own  92.10% of the company's stock. </p><h2>Phreesia News Roundup</h2><p>Here are the key news stories impacting Phreesia this week:</p><ul>   <li><span>Negative Sentiment: </span>Multiple law firms, including Rosen Law Firm, Faruqi &amp; Faruqi, Pomerantz, Bragar Eagel &amp; Squire, Gross Law Firm, Robbins LLP, and Gainey McKenna &amp; Egleston, announced or promoted class-action lawsuits against Phreesia, alleging potential securities fraud tied to the period from May 8, 2025 through March 30, 2026. <i></i><span>Article Title</span></li>   <li><span>Negative Sentiment: </span>The lawsuits and related investor alerts may increase legal costs, management distraction, and uncertainty around prior disclosures, which can weigh on investor sentiment toward the stock. <i></i><span>Article Title</span></li>   <li><span>Neutral Sentiment: </span>Phreesia’s latest quarterly results were mixed: revenue came in slightly above expectations, but EPS missed consensus, which may still be influencing how investors view the company’s fundamentals. </li>   <li><span>Neutral Sentiment: </span>Despite the recent news flow, analysts previously remained constructive overall, with several Buy/Outperform ratings and a median price target above the current share price, suggesting some longer-term optimism remains. </li> </ul><h2>About Phreesia</h2> (Get Free Report)<p>Phreesia, Inc <span>NYSE: PHR<span></span></span> is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company's cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.  </p><p>Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Phreesia</li><li>Viking Sails to All-Time Highs—Fundamentals Signal More to Come</li><li>Datavalut Gains Traction: 5 Reasons to Sell Now</li><li>TMC Stock: Why This Pre-Revenue Miner Is Worth Watching</li><li>The Power Grid Is Dying—Is It Time to Buy Its Replacement?</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBIUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBIUg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Phreesia Right Now?</h2><p>Before you consider Phreesia, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phreesia wasn't on the list.</p><p>While Phreesia currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Barclays has downgraded Phreesia (NYSE:PHR) from a 'strong-buy' to a 'hold' rating. Other analysts have also adjusted their ratings and target prices, with Mizuho lowering its target from $22 to $19 and DA Davidson from $35 to $30. Phreesia's stock has a consensus rating of 'Moderate Buy' and a target price of $20. The company reported a quarterly EPS of $0.02, missing estimates, with revenue of $127.07 million, up 15.9% year-over-year.</p>

Market Beat

Phreesia

Barclays

Mizuho Financial

Mizuho Financial Group, Inc.

Citizens Financial

Citigroup

Bank of Montreal

Waystar

Raymond James Financial

AllianceBernstein

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SR I

CITIZENS FINANCIAL GROUP INC 5% DEP SHS EA REP 1/40TH NON CUM SER E

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SER H

CITIGROUP INC 6.250 NON CUM SER II PFD WI

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

Phreesia (NYSE:PHR) Stock Rating Lowered by Barclays